STAT3 and cholangiocarcinoma: Additionally, in this case, Sorafenib-induced dephosphorylation of Tyr705 STAT3 is mediated by SHP2, and in cholangiocarcinoma cells, Sorafenib-induced dephosphorylation of Tyr705 p-STAT3 is inhibited by knocking down SHP2.